×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
LON:CLIN

Clinigen Group Share Forecast, Price & News

GBX 925
0.00 (0.00%)
(As of 04/4/2022)
Add
Compare
Today's Range
925
925
50-Day Range
925
925
52-Week Range
541.50
948.05
Volume
539,375 shs
Average Volume
1.83 million shs
Market Capitalization
£1.23 billion
P/E Ratio
64.69
Dividend Yield
0.82%
Price Target
GBX 740
30 days | 90 days | 365 days | Advanced Chart

Receive CLIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter.

CLIN Stock Forecast (MarketRank)

Overall MarketRank

1.43 out of 5 stars

Analyst Opinion: 1.3Community Rank: 5.0Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
Clinigen Group logo

About Clinigen Group (LON:CLIN)

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

CLIN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Delivery
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,000
Year Founded
N/A

Company Calendar

Last Earnings
9/17/2020
Today
6/29/2022

Price Target and Rating

Average Stock Price Forecast
GBX 740
High Stock Price Forecast
GBX 860
Low Stock Price Forecast
GBX 650
Forecasted Upside/Downside
-20.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.6
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£565.60 million
Cash Flow
GBX 88.30 per share
Book Value
GBX 341.90 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.23 billion
Optionable
Not Optionable
Beta
N/A














Clinigen Group Frequently Asked Questions

Should I buy or sell Clinigen Group stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Clinigen Group stock.
View analyst ratings for Clinigen Group
or view top-rated stocks.

What is Clinigen Group's stock price forecast for 2022?

5 Wall Street analysts have issued 1 year target prices for Clinigen Group's shares. Their CLIN stock forecasts range from GBX 650 to GBX 860. On average, they expect Clinigen Group's stock price to reach GBX 740 in the next twelve months. This suggests that the stock has a possible downside of 20.0%.
View analysts' price targets for Clinigen Group
or view top-rated stocks among Wall Street analysts.

How has Clinigen Group's stock performed in 2022?

Clinigen Group's stock was trading at GBX 915.50 at the beginning of 2022. Since then, CLIN shares have increased by 1.0% and is now trading at GBX 925.
View the best growth stocks for 2022 here
.

How were Clinigen Group's earnings last quarter?

Clinigen Group plc (LON:CLIN) announced its quarterly earnings data on Thursday, September, 17th. The company reported $65.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $63.50 by $2.10.
View Clinigen Group's earnings history
.

How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?

Clinigen Group declared a dividend on Thursday, September 16th. Shareholders of record on Thursday, December 2nd will be given a dividend of GBX 5.46 per share on Tuesday, January 4th. This represents a dividend yield of 0.92%. The ex-dividend date is Thursday, December 2nd. This is a positive change from Clinigen Group's previous dividend of GBX 2.15. The official announcement can be seen at this link.
View Clinigen Group's dividend history
.

Is Clinigen Group a good dividend stock?

Clinigen Group(LON:CLIN) pays an annual dividend of GBX 0.08 per share and currently has a dividend yield of 0.82%. The dividend payout ratio of Clinigen Group is 0.53%. This payout ratio is at a healthy, sustainable level, below 75%.
View Clinigen Group's dividend history.

Who are Clinigen Group's key executives?

Clinigen Group's management team includes the following people:
  • Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 54, Pay $662k)
  • Richard Paling, Interim Chief Financial Officer & Group Financial Controller
  • Mr. Sam Herbert, Chief Operating Officer
  • Rob Fox, VP of Investor Relations & Corp. Devel.
  • Ms. Amanda Miller, Gen. Counsel & Company Sec.
  • Mr. David Bryant, Director of Corp. Devel.
  • Jessica Archer, Global HR Director
  • Mr. Mark Corbett, Managing Director of Global Access Division
  • Mr. Johannes Willemse, Chief Commercial Officer (Age 54)
  • Mr. Ivo Timmermans M.D., MBA, Chief Medial Officer (Age 62)

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Applications (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), RTI International Metals (RTI), General Electric (GE) and NetApp (NTAP).

What is Clinigen Group's stock symbol?

Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How do I buy shares of Clinigen Group?

Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Clinigen Group's stock price today?

One share of CLIN stock can currently be purchased for approximately GBX 925.

How much money does Clinigen Group make?

Clinigen Group (LON:CLIN) has a market capitalization of £1.23 billion and generates £565.60 million in revenue each year.

How many employees does Clinigen Group have?

Clinigen Group employs 1,000 workers across the globe.

How can I contact Clinigen Group?

Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The official website for Clinigen Group is www.clinigengroup.com. The company can be reached via phone at +44-1283-495010.

This page (LON:CLIN) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.